Skip to content


Helsinki, 9 March 2015 at 8:00 am

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces the publication of its 2014 Annual Report. These documents are available on the “Investor Relations” section of the Company’s website at


The Annual Report contains the Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor’s Report.
A copy of the Annual Report is attached to this release.
Nexstim Plc
Janne Huhtala, CEO


For further information please visit or contact:
Nexstim +358 (0)40 8615046 Janne Huhtala, Chief Executive Officer
UB Capital Oy (Certified Adviser) +358 (0)9 2538 0225
Consilium Strategic Communications +44 (0)20 3709 5700 Mary-Jane Elliott / Ivar Milligan
About Nexstim Plc
Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim’s shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit

Source: Nexstim